WOKVAC Vaccine to Prevent Brain Metastases in Metastatic HER2 Positive Breast Cancer, SHIELD Trial
Open the official record
This page only displays public information reproduced from the official ClinicalTrials.gov record NCT07949760. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Single-Arm, Phase II Trial: Study of HER2+ Metastatic Breast Cancer Immunization to Enable CNS Lesion Defense (SHIELD)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This phase II trial tests how well the WOKVAC vaccine works in preventing brain metastases in patients with HER2 positive, hormone receptor negative or low breast cancer that has spread from where it first started (primary site) to other places in the body (metastatic). WOKVAC is a vaccine made from tumor-associated proteins, pUMVC3, IGFBP2, HER2, and IGF1R, and may help the body build an effective immune response to kill tumor cells. Sargramostim is a substance that helps make more white blood cells, especially granulocytes, macrophages, and cells that become platelets It is a cytokine that is a type of hematopoietic (blood forming) agent. Giving WOKVAC mixed with sargramostim may help prevent the development of brain metastases in patients with HER2 positive, hormone receptor negative or metastatic breast cancer.
Study identification
- NCT ID
- NCT07949760
- Recruitment status
- Not yet recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 52 participants
Conditions and interventions
Conditions
Interventions
- pUMVC3-IGFBP2-HER2-IGF1R Plasmid DNA Vaccine Biological
- Computed Tomography Procedure
- Magnetic Resonance Imaging Procedure
- Sargramostim Biological
- Tetanus and Diphtheria Toxoids Adsorbed Biological
- Biospecimen Collection Procedure
Biological · Procedure
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 30, 2026 (Estimated)
- Primary completion
- Dec 31, 2030 (Estimated)
- Completion
- Dec 31, 2035 (Estimated)
- Last update posted
- Nov 19, 2026
2026 – 2035
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Fred Hutch/University of Washington Cancer Consortium | Seattle | Washington | 98109 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07949760, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 19, 2026 · Synced Nov 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.